Spain· ES:96018001
RAPILYSIN 10 U, POLVO Y DISOLVENTE PARA SOLUCION INYECTABLE
A medicinal product containing reteplasa, registered in Spain by Actavis Group Ptc Ehf..
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- reteplasa
- Manufacturer
- Actavis Group Ptc Ehf.
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- June 3, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Reteplasa in 6 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandEcokinaseGalenus Mannheim GmbH
- BelgiumRapilysin 10 UActavis Group PTC
- United KingdomRapilysin 10unit powder and solvent for solution for injection vialsActavis UK Ltd
- IrelandRapilysin 10 U powder and solvent for solution for injection.Actavis Group hf
- NetherlandsRapilysin 10 U, poeder voor injectievloeistof 10 UActavis Group PTC ehf
- PolandRapilysinActavis Group PTC ehf.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/54c97539-03fc-4032-98f9-0713e0cea4bf GET /v1/drugs/54c97539-03fc-4032-98f9-0713e0cea4bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Uso Hospitalario",
"estado": "{\"aut\":859845600000,\"rev\":1729497545000}",
"nregistro": "96018001",
"substance": "reteplasa"
}See everything about reteplasa.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.